Biotech news summary, 16 October 2026

Today in brief

Osivax’s OVX836 flu vaccine missed its Phase 2b efficacy target, with an estimate of 24% that was not statistically significant.1 AstraZeneca and insitro signed a drug-discovery deal for MASH and cardiomyopathies, with $40 million upfront and about $1.46 billion in potential milestone payments.2

Osivax turns to vaccine combinations after OVX836 misses its Phase 2b target

OVX836 had estimated efficacy of 24% in Osivax’s Phase 2b trial, below its predefined 50% target, and the result was not statistically significant.1 The randomized, placebo-controlled Asuniva study enrolled 2,850 healthy adults aged 18 to 59 in Belgium, France, Finland and Germany.1

None of the reported efficacy estimates showed statistically significant protection: 28% against CDC-defined influenza-like illness, 27% against influenza A/H3 and 25% against A/H1N1pdm09.1 The vaccine had a favorable safety profile and prompted antibody and T-cell responses against influenza nucleoprotein, the viral protein OVX836 targets.1

Osivax is emphasizing OVX836 as a possible addition to seasonal flu vaccines, rather than mainly as a standalone alternative.1 The company plans to advance combination candidates through two partnerships, including an August agreement with GC Biopharma for a single-injection vaccine combining OVX836 and GC FLU.1 Osivax has not set a date for the next efficacy trial.1

AstraZeneca and insitro link AI drug discovery to up to $1.46 billion in milestones

AstraZeneca and insitro will use insitro’s Virtual Human platform to identify targets and develop potential therapies for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.2 3 insitro says the platform uses large-scale human and cellular data to identify disease biology.2

AstraZeneca will pay $40 million upfront and could pay about $1.46 billion in development and commercial milestones for exclusive worldwide rights to selected programs.2 3 insitro may also receive single-digit royalties on sales if any resulting drugs reach the market.2 3

AstraZeneca will lead clinical development and regulatory work, while insitro advances targets selected by AstraZeneca toward development candidates.3 AstraZeneca is testing its MASH drug AZD2389 in Phase II and discontinued AZD2693 after weak Phase II results.2

The day in numbers

24%

OVX836’s estimated efficacy in the Phase 2b flu-vaccine trial, below its 50% target and not statistically significant. 1
$40 million

Upfront payment AstraZeneca will make to insitro in their discovery and licensing deal. 2 3
About $1.46 billion

Potential development and commercial milestone payments to insitro, in addition to the upfront payment. 2 3